The practicable therapeutic strategy for beta-thalassemia thus involves editing human-peripheral-blood-mobilized CD34+ hematopoietic stem and progenitor cells (HSPSc) by ribonucleoprotein (RNP) electroporation. The gene discussed is CD34; the disease is Beta-thalassemia.